Lenz Robert A. 4
4 · Neumora Therapeutics, Inc. · Filed Feb 20, 2025
Insider Transaction Report
Form 4
Lenz Robert A.
Head of R&D
Transactions
- Sale
Common Stock
2025-02-18$1.67/sh−5,614$9,383→ 309,092 total
Footnotes (2)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.
- [F2]This transaction was executed in multiple trades in prices ranging from $1.66 to $1.695, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.